Efficient Suppression of Hepatitis C Virus Replication by Combination Treatment with miR-122 Antagonism and Direct-acting Antivirals in Cell Culture Systems

scientific article published on 03 August 2016

Efficient Suppression of Hepatitis C Virus Replication by Combination Treatment with miR-122 Antagonism and Direct-acting Antivirals in Cell Culture Systems is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1034385180
P356DOI10.1038/SREP30939
P932PMC publication ID4971519
P698PubMed publication ID27484655

P2093author name stringHong Tang
Minkyung Yi
Shuichi Kaneko
Masao Honda
Takayoshi Shirasaki
Tetsuro Shimakami
Fanwei Liu
Kazuhisa Murai
Masaya Funaki
Seishi Murakami
P2860cites workGlobal and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010Q21534928
Structural basis for viral 5'-PPP-RNA recognition by human IFIT proteinsQ24310342
Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-IQ24556673
Genetic variation in IL28B and spontaneous clearance of hepatitis C virusQ24596340
Regulation of hepatitis C virus translation and infectious virus production by the microRNA miR-122Q24609988
The yin and yang of hepatitis C: synthesis and decay of hepatitis C virus RNAQ26800446
Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cellsQ27473106
Structural basis of RNA recognition and activation by innate immune receptor RIG-IQ27674465
Global epidemiology of hepatitis C virus infectionQ27860799
Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNAQ27861124
Treatment of HCV infection by targeting microRNAQ29547712
IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapyQ29614896
Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infectionQ29615959
LNA-mediated microRNA silencing in non-human primatesQ29615962
Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis CQ29619541
Kinetic analyses reveal potent and early blockade of hepatitis C virus assembly by NS5A inhibitors.Q33934312
PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replicationQ34045444
Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectivesQ34045760
Hepatitis C virus genetics affects miR-122 requirements and response to miR-122 inhibitors.Q34539024
MicroRNA-122 antagonism against hepatitis C virus genotypes 1-6 and reduced efficacy by host RNA insertion or mutations in the HCV 5' UTR.Q34721015
Position-dependent function for a tandem microRNA miR-122-binding site located in the hepatitis C virus RNA genomeQ34795106
Protease Inhibitor–Resistant Hepatitis C Virus Mutants With Reduced Fitness From Impaired Production of Infectious VirusQ35164008
Adaptive mutations producing efficient replication of genotype 1a hepatitis C virus RNA in normal Huh7 cellsQ35702021
Stabilization of hepatitis C virus RNA by an Ago2-miR-122 complex.Q35735135
Interferon-free antiviral combination therapies without nucleosidic polymerase inhibitorsQ38274463
La protein is a potent regulator of replication of hepatitis C virus in patients with chronic hepatitis C through internal ribosomal entry site-directed translationQ38331129
The importance of resistance to direct antiviral drugs in HCV infection in clinical practiceQ38593397
Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virusQ39376758
Nonhepatic cell lines HeLa and 293 support efficient replication of the hepatitis C virus genotype 2a subgenomic replicon.Q40481063
Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapyQ41248646
Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials.Q41722679
In vitro antiviral activity and preclinical and clinical resistance profile of miravirsen, a novel anti-hepatitis C virus therapeutic targeting the human factor miR-122.Q42181792
P275copyright licenseCreative Commons Attribution 4.0 InternationalQ20007257
P6216copyright statuscopyrightedQ50423863
P407language of work or nameEnglishQ1860
P921main subjectHepatitis C virusQ708693
P304page(s)30939
P577publication date2016-08-03
P1433published inScientific ReportsQ2261792
P1476titleEfficient Suppression of Hepatitis C Virus Replication by Combination Treatment with miR-122 Antagonism and Direct-acting Antivirals in Cell Culture Systems
P478volume6

Reverse relations

cites work (P2860)
Q59350656Depletion of MicroRNA-373 Represses the Replication of Hepatitis C Virus via Activation of Type 1 Interferon Response by Targeting IRF5
Q89043628Differentiation in stem/progenitor cells along fetal or adult hepatic stages requires transcriptional regulators independently of oscillations in microRNA expression
Q55280981Host-targeting therapies for hepatitis C virus infection: current developments and future applications.
Q38289423Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial
Q52584714Unexpected Replication Boost by Simeprevir for Simeprevir-resistant Variants in Genotype 1a Hepatitis C Virus.

Search more.